Someone here owns exel, they also have data coming out in the near future. That one got slammed when study was a continue, not a halt. If I were to pick up one it might be exel: from a July 14th 2014 press release:
These positive top-line results from coBRIM represent an important milestone for melanoma patients and their physicians, and are the first of four anticipated phase 3 pivotal trial read-outs for Exelixis-discovered compounds in 2014,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Despite recent therapeutic innovations, BRAFV600 mutation-positive advanced melanoma can be difficult to treat due to the emergence of resistance. We look forward to the full presentation of the data later this year. If ultimately approved, we will execute on our collaborative U.S. co-promotion effort with Genentech and work alongside our partner to bring this important new therapeutic option to melanoma patients in need.”
In addition to the coBRIM results just announced, Exelixis anticipates delivering on the following key clinical development initiatives before the end of 2014:
Top-line results from pivotal phase 3 studies COMET-1 (overall survival endpoint) and COMET-2 (pain palliation endpoint) of cabozantinib in metastatic castration-resistant prostate cancer;
Top-line results from the overall survival analysis of EXAM, the phase 3 pivotal trial of cabozantinib in progressive, metastatic medullary thyroid cancer; and
Completing enrollment in METEOR, the phase 3 pivotal trial of cabozantinib in metastatic renal cell cancer.
Agen has a nice pipeline too, a little position in each works.
Said BUY IT phase 3 data at hand.
The pps will be in direction relation to revenue and eps. with a premium for any non marketed phase 2-3 items. Throwing a number out there be it 17, 30, 50, or 100 is meaningless. Through out a revenue number to go with a price target, a percent market share achieved per indication and you will have my attention. Picking a number like 17 equates to about 400-500m in revenue, Opko will do more than that by a few billion.
U R in at a better price than I am, so I am glad about that. I hate when some one buys a stock I am in and it then drops, ouch, I always feel guilty. But I buy hold, 3 year windows, most know that, daily moves mean nothing. This one will take time, the ATM hurts it short term. Hope I am right on both, time will tell, 2016 both should be up 2-4 fold if 10% of the pipelines pan out.
So realistically how are shorts going to find 17m shares to cover, funds usually do not trade daily, only 12.5m in retail hands, funds net buyers last Q by 1.8m, 10 days to cover. This item is set up nicely to rocket on positive phase 3 news.
First to cover wins, period.
Cover, is the best, safest play, buy puts.
getting arry back near year high. Under 5.00 IS A BUY.
as evinced by onty move too.
9.00, short term, but longer term no higher target but bullish. From Piper:
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.
Frost is doing a 2 billion dollar share buy back program for Opko using his cash, not Opko's. So far their is another 1.5B in available cash to buy shares, lol. Opko's hemophilia drug looks to have an advantage over Biogen's newly approved drug. Biogen's injections are every 4 days, two indications, Opko's every 7 days, 4 indications, so broader applicability and less frequent dosage, a 7 billion dollar market according to Biogen.
over 18% on the puma news. Guess market is figuring if the puma pan-her worked the arry/onty will too. The arry/onty is only phase 1, arry does also own a phase2 so those drugs are about 3 years away. Arry is a 2015-2016 story, onty the same.
Arry drugs in phase 1-2 using her1-her2 mechanism.
Not sure but puma ( pbyi up 287% ) on her1, her2 inhibitor drug and Arry Mek drugs might have a similar mechanism aimed at shutting down cell growth mechanism. Someone with a better medical background than I have might clarify. I believe one of our mek drugs had similar results in phase 2 for at least one indication though most phase 3 studies here are a year or two from completion.